C

Cardiff Oncology

D
CRDF
USD
0.055
(2.2267%)
Market Closed
17,534.00
Volume
-1.04
EPS
-
Div Yield
-2.750000
P/E
117,537,825.85
Market Cap
Today
2.2267%
1 Week
-0.980%
1 Month
5.428%
6 Months
-48.045%
12 Months
56.832%
Year To Date
71.769%
All Time
-99.219%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

EV Maker Fisker Files for Bankruptcy

18.06.2024
Stocks news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news

Tesla Sales Drop Amid Intensifying EV Competition

03.04.2024
Stocks news

EV Maker Fisker in Grave Trouble as Shares Tank

27.03.2024
Stocks news
More
Related Instruments
PLTR
PLTR
0.43
(1.1813%)
USD
U
UPST
1.64
(4.2786%)
USD
A
AI
0.45
(1.9338%)
USD
SNOW
SNOW
3.27
(2.9518%)
USD
DDOG
DDOG
2.37
(2.0946%)
USD
F
FSLY
0.1
(1.4205%)
USD
R
RXT
0
(0%)
USD
F
FVRR
0.56
(2.2134%)
USD
T
TNL
1.53
(3.5865%)
USD
O
OSTK
(%)
USD

Title:
Cardiff Oncology

Sector:
Healthcare
Industry:
Biotechnology
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Do you need help or have a question?
Contact Us